Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 8
2013 14
2014 11
2015 16
2016 12
2017 13
2018 20
2019 19
2020 20
2021 21
2022 15
2023 9
2024 8
2025 11
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Wada N, Mizunaga M, Abe N, Miyauchi K, Kobayashi S, Ohtani M, Tsunekawa R, Nagabuchi M, Morishita S, Ohyama T, Yamaguchi S, Iuchi H, Noda T, Saga Y, Motoya T, Kawakami N, Nishihara M, Numata A, Kakizaki H. Wada N, et al. World J Urol. 2024 Mar 2;42(1):113. doi: 10.1007/s00345-024-04799-4. World J Urol. 2024. PMID: 38431689 Clinical Trial.
The patients were assigned to Group MV (mirabegron for 8 weeks, followed by vibegron for 8 weeks) or group VM (vibegron for 8 weeks, followed by mirabegron for 8 weeks). ...The mean change in the daytime frequency was greater in the vibegron than in the mirabegro …
The patients were assigned to Group MV (mirabegron for 8 weeks, followed by vibegron for 8 weeks) or group VM (vibegron for 8 weeks, …
Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.
Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elía E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM. Cypess AM, et al. Cell Metab. 2015 Jan 6;21(1):33-8. doi: 10.1016/j.cmet.2014.12.009. Cell Metab. 2015. PMID: 25565203 Free PMC article. Clinical Trial.
Here we determined the ability of 200 mg oral mirabegron (Myrbetriq, Astellas Pharma, Inc.), a beta3-AR agonist currently approved to treat overactive bladder, to stimulate BAT as compared to placebo. Mirabegron led to higher BAT metabolic activity as measured via ( …
Here we determined the ability of 200 mg oral mirabegron (Myrbetriq, Astellas Pharma, Inc.), a beta3-AR agonist currently approved to …
Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.
Stanley RF, Meyer I, Blanchard CT, Richter HE. Stanley RF, et al. Int Urogynecol J. 2024 Aug;35(8):1709-1717. doi: 10.1007/s00192-024-05835-y. Epub 2024 Aug 5. Int Urogynecol J. 2024. PMID: 39101958 Free PMC article. Clinical Trial.
INTRODUCTION AND HYPOTHESIS: To compare change in urgency urinary incontinence episodes (UUIEs) in women undergoing posterior tibial nerve stimulation (PTNS) plus mirabegron versus PTNS plus placebo for the treatment of refractory urgency urinary incontinence (UUI). ...Par …
INTRODUCTION AND HYPOTHESIS: To compare change in urgency urinary incontinence episodes (UUIEs) in women undergoing posterior tibial nerve s …
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.
Menghoum N, Badii MC, Leroy M, Parra M, Roy C, Lejeune S, Vancraeynest D, Pasquet A, Brito D, Casadei B, Depoix C, Filippatos G, Gruson D, Edelmann F, Ferreira VM, Lhommel R, Mahmod M, Neubauer S, Persu A, Piechnik S, Hellenkamp K, Ikonomidis I, Krakowiak B, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Gerber BL, Balligand JL, Beauloye C, Pouleur AC. Menghoum N, et al. Cardiovasc Diabetol. 2025 Mar 22;24(1):134. doi: 10.1186/s12933-025-02688-7. Cardiovasc Diabetol. 2025. PMID: 40121452 Free PMC article. Clinical Trial.
TRIAL REGISTRATION: Characterization of Heart Failure With Preserved Ejection Fraction; Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure (Beta3_LVH). ...
TRIAL REGISTRATION: Characterization of Heart Failure With Preserved Ejection Fraction; Assessment of Efficacy of Mirabegron, a New b …
Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial.
Hsiao SM. Hsiao SM. Sci Rep. 2025 Aug 21;15(1):30687. doi: 10.1038/s41598-025-15780-5. Sci Rep. 2025. PMID: 40841399 Free PMC article. Clinical Trial.
The effect of nighttime dosing versus daytime dosing of mirabegron is undetermined. Thus, this study aimed to clarify the effect of nighttime versus daytime mirabegron dosing. Between August 2017 and August 2023, all women with overactive bladder syndrome were rando …
The effect of nighttime dosing versus daytime dosing of mirabegron is undetermined. Thus, this study aimed to clarify the effect of n …
Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuhara H. Kinjo M, et al. Int Urogynecol J. 2023 Apr;34(4):853-859. doi: 10.1007/s00192-022-05261-y. Epub 2022 Jun 14. Int Urogynecol J. 2023. PMID: 35699775 Clinical Trial.
INTRODUCTION AND HYPOTHESIS: We aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in treatment-naive women with overactive bladder (OAB). METHODS: Women being treated with mirabegron 50 mg were allocated to MS and …
INTRODUCTION AND HYPOTHESIS: We aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron …
Comparison of stent related symptoms in patients taking mirabegron, solifenacin, or tamsulosin: A double blinded randomized clinical trial.
Chandna A, Kumar S, Parmar KM, Sharma AP, Devana SK, Mete UK, Singh SK. Chandna A, et al. Urologia. 2022 Nov;89(4):589-596. doi: 10.1177/03915603211048153. Epub 2021 Oct 1. Urologia. 2022. PMID: 34596484 Clinical Trial.
BACKGROUND: The present study aims to assess the efficacy of mirabegron, a novel beta-3 agonist for ameliorating stent related symptoms (SRSs) as compared to tamsulosin and solifenacin. METHODS: Total of 150 patients undergoing ureteral stent placement following ureterosco …
BACKGROUND: The present study aims to assess the efficacy of mirabegron, a novel beta-3 agonist for ameliorating stent related sympto …
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E. Chapple CR, et al. Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18. Eur Urol. 2020. PMID: 31635815 Free article. Clinical Trial.
CONCLUSIONS: Data from this integrated database of 10 mirabegron studies reaffirm the safety and efficacy profiles of mirabegron, solifenacin, and tolterodine in adults of different age groups and sexes. ...No new safety concerns were identified, and mirabegron …
CONCLUSIONS: Data from this integrated database of 10 mirabegron studies reaffirm the safety and efficacy profiles of mirabegron …
The Efficacy and Safety Between Intradetrusor OnabotulinumtoxinA Injection and Combined Pharmacotherapy in Patients With Refractory Overactive Bladder: A Randomized Controlled Trial.
Hsieh MH, Hwang JC, Su TH, Lau HH. Hsieh MH, et al. J Urol. 2025 Oct;214(4):344-353. doi: 10.1097/JU.0000000000004660. Epub 2025 Jul 1. J Urol. 2025. PMID: 40590342 Free PMC article. Clinical Trial.
MATERIALS AND METHODS: In this single-center, open-label, randomized trial, patients with urodynamically confirmed detrusor overactivity and persistent symptoms despite at least 2 months of single pharmacotherapy were randomized to receive onabotulinumtoxinA injection (100 U) or …
MATERIALS AND METHODS: In this single-center, open-label, randomized trial, patients with urodynamically confirmed detrusor overactivity and …
Assessment of efficacy of mirabegron, solifenacin, tadalafil 5 mg and combination therapy in female patients with overactive bladder: a double blinded multicenter prospective placebo-controlled trial.
Zeinelabden KM, Elsayed EA, Aziz M, Mamdoh H. Zeinelabden KM, et al. Minerva Urol Nephrol. 2025 Jun;77(3):383-395. doi: 10.23736/S2724-6051.25.06129-4. Epub 2025 Apr 23. Minerva Urol Nephrol. 2025. PMID: 40265720 Free article. Clinical Trial.
BACKGROUND: This study assess the efficacy of mirabegron, solifenacin, tadalafil 5 mg, and tadalafil 5 mg combination with solifenacin and mirabegron in the treatment of female patients with overactive bladder (OAB), comparing these to a placebo in a double-blinded, …
BACKGROUND: This study assess the efficacy of mirabegron, solifenacin, tadalafil 5 mg, and tadalafil 5 mg combination with solifenaci …
151 results